NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has been officially accepted into the NVIDIA Connect Program, a global initiative supporting innovative software and technology companies working with advanced computing and AI platforms. Acceptance into the NVIDIA Connect Program... Read More

Collaborative program with the U.S. Department of Veterans Affairs aims to validate GDNF as a first-in-class biologic for obesity and hepatic health. NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a biopharmaceutical company focused on developing breakthrough therapies for metabolic, dermatologic, and inflammatory diseases, today announced the initiation of a U.S. Department of Veterans... Read More

>80% KIT knock-down and significant tumor-volume reduction in systemic mastocytosis and GIST models; GLP-validated bio analytics complete; Japan Patent protects through 2039 as IND work advances. Planned Next Steps (Near-Term): Complete GLP toxicology and CMC packages; submit IND. Initiate Phase 1/2 dose-escalation/expansion study in advanced systemic mastocytosis and other KIT-driven tumors with translational biomarkers of... Read More

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for... Read More

Presentation to highlight advancements in Hoth's clinical pipeline, including HT-001 for cancer-therapy-induced rash and HT-KIT, a novel oncology program targeting KIT-driven tumors NEW YORK , Oct. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a clinical-stage biopharmaceutical company focused on developing first-in-class therapeutics for dermatological, oncology, and Alzheimer's, today announced that... Read More

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment. Key Highlights U.S. Provisional Patents filed expanding HT-001's therapeutic reach. Indications covered:... Read More

NEW YORK , Sept. 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced a comprehensive shareholder update, underscoring momentum across its lead clinical programs and corporate strategy. With HT-001 advancing globally, HT-KIT achieving key validation milestones, the expansion of its treasury reserve strategy to include Bitcoin , Ethereum , and Solana ,... Read More

NEW YORK , Sept. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced it has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi). The submission marks a... Read More

NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc . (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform , a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability . This adoption positions Hoth at the forefront of AI-driven drug development ,... Read More

NEW YORK , Sept. 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced combined positive findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT, including compelling anti-tumor efficacy, a clean safety profile, and new GLP-validated bioanalytical results that exceeded internationally recognized regulatory... Read More

The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries NEW YORK , July 29, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced its engagement with ICON Clinical Research Limited ("ICON") to expand it's Phase II Clinical Trial for cancer patients suffering from skin toxicities associated... Read More

NEW YORK , July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic... Read More

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK , June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint... Read More

Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities. Hoth Therapeutics will host a Key Opinion Leader (KOL) event on, at 3:30PM EST to highlight recent clinical progress with HT-001, a novel topical therapeutic developed to address EGFR inhibitor-induced skin toxicities in cancer patients. This event will feature insights... Read More

Developed to address EGFR inhibitor-induced skin toxicities in cancer patients NEW YORK , June 23, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they will host a virtual Key Opinion Leader (KOL) event on Tuesday, June 24, 2025, at 3:30PM EST . Access/join the event through the following link:... Read More

NEW YORK , June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq's minimum bid price requirement. On June 18, 2025 , the Company received formal notice from the Nasdaq Listing Qualifications Department confirming that Hoth's common stock closed at or above the $1.00... Read More

HOTH announces strong preclinical data for HT-KIT showing dose-dependent liver activity with zero observed toxicity – key milestone as the company prepares for IND filing. Study Results: Liver weight increased from 1.11g → 1.32g across 0 → 3.0 mg/kg No adverse effects on kidney, spleen, or thymus 100% clean safety profile — no visible lesions or gross pathology Validates safety of HT-KIT in vivo Robb Knie , CEO: "These... Read More

NEW YORK , June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients, today announced that Robb Knie , Chief Executive Officer, is scheduled to attend the BIO International Convention, in Boston, MA , June 16-19,2025. The BIO International Convention is the largest and most comprehensive event for... Read More

Protection through 2039, ensuring long-term commercial exclusivity. NEW YORK , June 12, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the HT-KIT platform. The patent was officially granted by the Japan Patent Office on May 7, 2025 , and exclusive protection is... Read More

Premier Research to support submission of an Expanded Access Program (EAP) application. This move positions Hoth to offer compassionate access to HT-001 for cancer patients suffering from painful and debilitating skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor therapies—an area of high unmet medical need. "We're seeing encouraging signals from our open-label Phase 2a cohort and are taking bold... Read More

Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK , June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today announced a Key Opinion Leader (KOL) event showcasing HT-001, its novel... Read More

In the news release, Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers, issued 12-May-2025 by Hoth Therapeutics, Inc. over PR Newswire, we are advised by the company that the 3rd bullet section, 2nd bullet should read "Significant inhibition of tumor growth". The complete, corrected release follows: HT-KIT dramatically suppresses... Read More

HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity. IND filing expected early 2026, opening pathway to first-in-human trials. Preclinical Milestones: Over 80% reduction in KIT expression in vitro using cancer cell lines harboring activating KIT mutations. Significant inhibition... Read More

Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK , April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc . (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO),... Read More

Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor- Induced Skin Toxicities Key Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7.... Read More

NEW YORK , April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1... Read More

Results underscore the dual-action profile of HT-ALZ—impacting both pathology and symptomology. NEW YORK , April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced groundbreaking preclinical data supporting the therapeutic potential of its lead Alzheimer's candidate, HT-ALZ , in improving cognitive... Read More

NEW YORK , March 31, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that it has received an official Filing Receipt from the United States Patent and Trademark Office (USPTO) for a new patent application related to the proprietary formulation of HT-001, the Company's lead clinical asset. This newly filed application seeks to expand the... Read More

NEW YORK , March 26, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. ( NASDAQ: HOTH ), a biopharmaceutical company focused on developing first-in-class therapies for allergic and inflammatory diseases, today announced two major developments in the ongoing advancement of its proprietary antisense oligonucleotide (ASO) cancer fighting drug candidate, HT-KIT . The Company has filed amended claims with the U.S. Patent and Trademark... Read More

New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 hours post-treatment, while the lower dose led to delayed but substantial cell death at 72 hours. Decreased Tumor Cell Proliferation – HT-KIT treatment inhibited cell growth and proliferation in GIST-T1 cells, as confirmed by... Read More

HT-001 is being developed to alleviate the adverse dermatological effects experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor treatments. With positive progress in ongoing clinical studies, Hoth Therapeutics aims to provide patients access to HT-001 outside of traditional clinical trials through the Expanded Access Program (EAP), commonly known as "compassionate use." NEW YORK , March... Read More

The data will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting, which takes place March 7-11, 2025 , highlighting HT-001 as a potential breakthrough therapy for EGFR inhibitor-induced dermatologic toxicities. The recent case study will be highlighted that demonstrated the efficacy of HT-001 2% cream in a 59-year-old patient with metastatic breast cancer undergoing treatment with paclitaxel,... Read More

Research Demonstrates GDNF's Ability to Prevent and Reverse Obesity by Enhancing Fat Metabolism and Energy Expenditure Hoth is developing this therapeutic in Partnership with the Department of Veterans Affairs Key Findings from the Study: Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet. Enhanced Fat Burning... Read More

NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) , a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to advance research for its cancer-fighting therapeutic, HT-KIT. This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step... Read More

NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth Therapeutics"), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). The Company received written... Read More

IP will be used to pursue further indications for HT-001 Cancer Therapeutic NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio through the acquisition and expansion of patent applications to its innovative therapeutic pipeline These newly secured patents reflect Hoth's commitment to... Read More

NEW YORK , Jan. 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Officer, is scheduled to attend the Sequire Investor Summit. To learn more about the Sequire Investor Summit, please visit https://puertorico.srax.com/ . About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to... Read More

The Company affirms that it has no plans for a public or private offering at this time. Hoth's financial position remains robust, with a strong balance sheet that includes over $10 million in cash and no debt. Hoth is pleased to report that enrollment in the HT-001 clinical trial is proceeding as planned, with all trial sites now active and enrolling participants. NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Hoth Therapeutics,... Read More

Highlights: 100% of Patients in Cohort 1 Achieve Primary Efficacy Endpoint No Treatment-Related Adverse Effects Observed Preserves Cancer Treatment Efficacy with Zero Dose Reductions NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2a clinical... Read More

Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001 NEW YORK , Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S.... Read More

NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin . "As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb... Read More

NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency... Read More

NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical... Read More

Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical... Read More

Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK , Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH)... Read More

Cancer Patient Ceased Treatment After One Week Due to Rapid Success In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment... Read More

Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT NEW YORK , Aug. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic . HT-KIT research, which was... Read More

Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients. HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease The pre-clinical research shows compelling evidence... Read More

Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health NEW YORK , July 16, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH ), a patient-focused biopharmaceutical company, today announced that it has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment... Read More

Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary data NEW YORK , June 10, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a joint development agreement with Wise Systems International SRL to leverage artificial intelligence utilizing the BioNeMo AI platform of Nvidia. BioNeMo provides... Read More

NEW YORK , May 1, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Officer, is scheduled to attend the EF Hutton Annual Global Conference in New York , NY. To learn more about the EF Hutton Annual Global Conference please visit https://efhutton.com/conference/ . About Hoth Therapeutics, Inc. Hoth Therapeutics is a clinical-stage... Read More

NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of the Company originally issued in January 2023 , having an exercise price of $5.00 per share, at a reduced exercise... Read More

Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program NEW YORK , March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai... Read More

HT-ALZ emerges as a promising novel solution for combating neuroinflammation and cognitive deficits associated with Alzheimer's Disease. NEW YORK , March 19, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), is pleased to unveil positive pre-clinical research showcasing the potential of HT-ALZ, an innovative Alzheimer's disease therapeutic. Targeting the Substance P/Neurokinin 1 Receptor pathway, HT-ALZ emerges as... Read More

NEW YORK , Feb. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc . (NASDAQ:HOTH), a patient-focused biopharmaceutical company , today announced that it will continue its work with Venable, LLP to develop and protect its intellectual property. Venable is an American Lawyer Global 100 law firm that serves as primary counsel to a worldwide clientele of large and mid-sized organizations and nonprofits and individuals. With more... Read More

Hoth's HT-KIT has received FDA Orphan Drug Status and Continues to Show Positive Study Results in Treating Mast Cell-Derived Cancers NEW YORK , Feb. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a... Read More

NEW YORK , Feb. 13, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Officer, is scheduled to attend the BIO CEO and Investor Conference in New York , NY. To learn more about BIO CEO and Investor Conference please visit https://bcic.bio.org/ . About Hoth Therapeutics, Inc. Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical... Read More

Patients will be able to enroll in trial at any time and regardless of failure from other therapeutics NEW YORK , Jan. 18, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001, which is being developed... Read More

NEW YORK , Dec. 27, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001. This First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors... Read More

NEW YORK , Dec. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the U.S. Food and Drug... Read More

Hoth intends to continue development under Orphan Drug Designation NEW YORK , Nov. 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for its HT-KIT therapeutic. The Pre-IND meeting was completed through written responses... Read More

NobleCon is the preeminent showcase of small and microcap companies NEW YORK , Nov. 10, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Robb Knie , Chief Executive Officer, is scheduled to present at the NobleCon 19 th Annual Emerging Growth Investor Conference in Boca Raton, FL. To learn more about NobleCon and registration to attend or scheduling a one-on-one... Read More

The new wholly owned subsidiary will screen for rare disease therapeutics. NEW YORK , Oct. 5, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company , today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases. Hoth will... Read More

NEW YORK , Oct. 2, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the Pre-IND meeting requested on September 8 th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023 . HT-KIT is an antisense oligonucleotide that targets the... Read More

NEW YORK , Sept. 15, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) ("Hoth" or the "Company"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share... Read More

NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $2.63 per share of common stock (or common stock equivalent in lieu thereof) in a registered direct... Read More

Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML Positive Preclinical Results of Novel HT-KIT Therapeutic Performed at NC State University NEW YORK , Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-KIT, a new molecular entity, for the treatment of... Read More

HT-KIT received Orphan Drug Designation from FDA for its mRNA Frame Shifting Cancer Therapeutic Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has submitted a request for a Pre-Investigational... Read More

78% of patients reported that their overall health had improved since starting BioLexa as compared to 22% stating that there was no change in their health, or their health was worse. DLQI found that BioLexa use led to a 46% improvement in patient quality of life whereas placebo had no effect. NEW YORK , Sept. 6, 2023... Read More

HT-ALZ Showed Improvement on Several Tests of Cognitive Function HT-ALZ Showed Positive Benefits with Reductions in Anxiety Completed Dose Response Study Leads Hoth to Begin Formulation Development NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today... Read More

NEW YORK , July 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). Robb Knie , Chief Executive Officer of Hoth Therapeutics, stated, "There is a significant unmet... Read More

FDA Approved Trial Now Has Two Sites Approved with Additional Sites in Approval Process Recruitment of Patients to Accelerate NEW YORK , July 19, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has received approval from the Food & Drug Administration ("FDA") for a protocol change in its Phase 2a clinical trial of HT-001. Participants will... Read More

Hoth achieves milestone of multiple sites to host trial NEW YORK , June 14, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received written approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of... Read More

Higher Dosing Shows Positive Effects on Cognitive Function NEW YORK , June 6, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-ALZ a therapeutic in development for the treatment of Alzheimer's disease achieved positive preclinical results that outpaced its pervious study. In particular, the higher dose appears to be most beneficial in a spatial... Read More

Hoth to Concentrate on its Current Pipeline and Continue Phase 2 Clinical Study Hoth Has Over Twelve Months Cash on Balance Sheet NEW YORK , May 12, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company , today announced that they have entered into a mutual agreement with Algorithm Sciences, Inc. ("Algorithm") to terminate their previously announced decision to merge,... Read More

Anthony Zook , formerly of Astra Zeneca, to be named Chairman of The Board Mike Tilton to be named Chief Executive Officer of the Combined Company Algorithm pipeline focused on Pulmonary Arterial Hypertension (PAH) a rare disease with a prevalence of ~100,000 patients in the US NEW YORK , April 26, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced it has... Read More

NEW YORK , March 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company , today announced the activation of Washington University School of Medicine in St. Louis as the first clinical site in the CLEER-001 Phase 2a clinical trial of HT-001 for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR... Read More

Strengthens Measures to Safeguard Shareholder Interests through ShareIntel's Investigation and Due Diligence Services for Illegal Short Selling NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company , today announced that it has entered into a service agreement with Shareholder Intelligence Services, LLC ("ShareIntel"), a patented compliance driven SAAS... Read More

HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model and Results Show Reduced Anxiety and Improved Performance NEW YORK , Feb. 8, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model (aged APP/PS1+/- mice), supporting... Read More

Patient Recruitment Underway NEW YORK , Jan. 25, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has selected 3 of its clinical sites for its Phase 2a clinical trial for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. EGFR inhibitors are critical therapeutic agents for the... Read More

NEW YORK , Jan. 3, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the "Company" or "Hoth"), a patient-focused biopharmaceutical company, today announced the closing of its previously announced private placement of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase shares of common stock priced at-the-market under Nasdaq rules, resulting in gross proceeds to the Company of $10 million... Read More

NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock equivalent in lieu thereof) and warrants to purchase up to an aggregate of 2,500,000 shares of common stock, at a purchase price of $5.00... Read More

On-track to initiate Phase 2 trial in Q1 2023 NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor... Read More

Clinical trial to begin early 2023 for Cancer patients NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on December 1, 2022 . The IND application supports a proposed indication of treatment for rash and skin disorders... Read More